Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Ginkgo Bioworks to Improve Novo Nordisk’s Chronic Disease Medications Manufacturing Over 5 Years

Apr 10, 2024

Boston-based Ginkgo Bioworks announced on 10 April 2024 an expansion of its partnership with global healthcare leader, Novo Nordisk. This extended collaboration, set to span five years, is targeting improving the manufacturing of Novo Nordisk’s medicines with a focus on chronic diseases including diabetes and obesity.

Ginkgo Bioworks, known for its expertise in cell programming and biosecurity, will bring its synthetic biology platform to optimize Novo Nordisk’s R&D pipeline for serious chronic diseases.

This news follows the 25 March 2024 announcement by Novo Nordisk of its acquisition of Cardior Pharmaceuticals for (up to) € 1.025B.